JP2016511005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511005A5 JP2016511005A5 JP2016501560A JP2016501560A JP2016511005A5 JP 2016511005 A5 JP2016511005 A5 JP 2016511005A5 JP 2016501560 A JP2016501560 A JP 2016501560A JP 2016501560 A JP2016501560 A JP 2016501560A JP 2016511005 A5 JP2016511005 A5 JP 2016511005A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- mirna
- cells
- antibody
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004962 mammalian cell Anatomy 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 57
- 238000004113 cell culture Methods 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 21
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 20
- 108091034117 Oligonucleotide Proteins 0.000 claims description 18
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 15
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 12
- 210000003734 kidney Anatomy 0.000 claims description 11
- 229940122938 MicroRNA inhibitor Drugs 0.000 claims description 10
- 239000002679 microRNA Substances 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 241000282693 Cercopithecidae Species 0.000 claims description 5
- 102000018697 Membrane Proteins Human genes 0.000 claims description 5
- 108010052285 Membrane Proteins Proteins 0.000 claims description 5
- 108700011259 MicroRNAs Proteins 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 241000282465 Canis Species 0.000 claims description 3
- 241000699800 Cricetinae Species 0.000 claims description 3
- 241000699802 Cricetulus griseus Species 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 101710163270 Nuclease Proteins 0.000 claims description 3
- 230000003302 anti-idiotype Effects 0.000 claims description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 238000003209 gene knockout Methods 0.000 claims description 3
- 210000003292 kidney cell Anatomy 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 108091035155 miR-10a stem-loop Proteins 0.000 claims description 3
- 108091062762 miR-21 stem-loop Proteins 0.000 claims description 3
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims description 3
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims description 3
- 108091070501 miRNA Proteins 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 210000003501 vero cell Anatomy 0.000 claims description 3
- 108091028684 Mir-145 Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- -1 miR-101 Proteins 0.000 claims description 2
- 108091027943 miR-16 stem-loop Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 3
- 239000013598 vector Substances 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 101710131422 E3 ubiquitin-protein ligase UHRF2 Proteins 0.000 description 1
- 102100024748 E3 ubiquitin-protein ligase UHRF2 Human genes 0.000 description 1
- 102000049982 HMGA2 Human genes 0.000 description 1
- 108700039143 HMGA2 Proteins 0.000 description 1
- 101150073387 Hmga2 gene Proteins 0.000 description 1
- 101000954986 Homo sapiens Merlin Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101001061942 Homo sapiens Ras-related protein Rab-40C Proteins 0.000 description 1
- 102100037106 Merlin Human genes 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102100029539 Ras-related protein Rab-40C Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782180P | 2013-03-14 | 2013-03-14 | |
| US61/782,180 | 2013-03-14 | ||
| PCT/US2014/024512 WO2014159633A1 (en) | 2013-03-14 | 2014-03-12 | Recombinant polypeptide production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511005A JP2016511005A (ja) | 2016-04-14 |
| JP2016511005A5 true JP2016511005A5 (enExample) | 2017-04-13 |
| JP6445516B2 JP6445516B2 (ja) | 2018-12-26 |
Family
ID=51625216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501560A Active JP6445516B2 (ja) | 2013-03-14 | 2014-03-12 | 組換えポリペプチドの生産 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10006026B2 (enExample) |
| EP (1) | EP2971035B1 (enExample) |
| JP (1) | JP6445516B2 (enExample) |
| CN (1) | CN105229159B (enExample) |
| AU (1) | AU2014244588B2 (enExample) |
| CA (1) | CA2902581C (enExample) |
| ES (1) | ES2743506T3 (enExample) |
| WO (1) | WO2014159633A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| EP3240894B1 (en) * | 2014-12-23 | 2021-01-27 | University of Georgia Research Foundation | RECOMBINANT CELLS COMPRISING miRNA MIMICS |
| US10383935B2 (en) * | 2015-09-23 | 2019-08-20 | Regents Of The University Of Minnesota | Methods of making and using live attenuated viruses |
| CN111148835A (zh) * | 2017-10-02 | 2020-05-12 | 阿斯利康(瑞典)有限公司 | 用于增加蛋白产量的细胞系和方法 |
| WO2019227259A1 (zh) * | 2018-05-26 | 2019-12-05 | 深圳市博奥康生物科技有限公司 | 一种基于哺乳动物病毒的介导miRNA过表达方法 |
| WO2019227253A1 (zh) * | 2018-05-26 | 2019-12-05 | 深圳市博奥康生物科技有限公司 | miRNA-21过表达载体的构建及其应用 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| CN117535292B (zh) * | 2023-11-01 | 2025-05-09 | 新乡医学院 | let-7a在CHO细胞重组蛋白表达中的应用、表达系统 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632672B2 (en) * | 1998-08-19 | 2003-10-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for genomic modification |
| EP1833961B1 (en) * | 2004-10-15 | 2011-07-20 | Monell Chemical Senses Center | Methods for culturing mammalian taste cells |
| US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| CN101541972A (zh) * | 2006-08-04 | 2009-09-23 | 都柏林城市大学 | 生产重组生物产品的方法 |
| EP2054529B1 (en) | 2006-08-25 | 2014-03-26 | Duke University | Methods for in vivo identification of endogenous mrna targets of micrornas |
| US20110098346A1 (en) * | 2008-05-19 | 2011-04-28 | Agency For Science, Technology And Research | Nucleic acid molecule and method of targeting gene expression to gliomas |
| EP2326730B1 (en) * | 2008-08-19 | 2014-03-19 | Maine Institute For Human Genetics And Health | Micro rna (mirna) and neurofibromatosis type 1 : a role in diagnosis and therapy |
| US20130177624A1 (en) * | 2009-05-08 | 2013-07-11 | David Brian Corry | Mirna expression in allergic disease |
| CN102712904A (zh) * | 2009-11-11 | 2012-10-03 | 桑福德—伯恩哈姆医学研究协会 | 用于产生和调节iPS细胞的方法及其组合物 |
| AR093183A1 (es) | 2010-12-31 | 2015-05-27 | Anthrogenesis Corp | Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras |
-
2014
- 2014-03-12 US US14/775,233 patent/US10006026B2/en active Active
- 2014-03-12 EP EP14776495.5A patent/EP2971035B1/en active Active
- 2014-03-12 CN CN201480013725.2A patent/CN105229159B/zh active Active
- 2014-03-12 WO PCT/US2014/024512 patent/WO2014159633A1/en not_active Ceased
- 2014-03-12 CA CA2902581A patent/CA2902581C/en active Active
- 2014-03-12 JP JP2016501560A patent/JP6445516B2/ja active Active
- 2014-03-12 ES ES14776495T patent/ES2743506T3/es active Active
- 2014-03-12 AU AU2014244588A patent/AU2014244588B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016511005A5 (enExample) | ||
| JP7440569B2 (ja) | 癌の治療に用いるための細胞傷害誘導治療剤 | |
| CN113874400B (zh) | 抗Vβ17/抗CD123双特异性抗体 | |
| US20210292392A1 (en) | Anti-sars-cov-2 antibodies and uses thereof | |
| AU2017331256B2 (en) | CD123 binding proteins and related compositions and methods | |
| JP7269167B2 (ja) | モジュラー四価二重特異性抗体プラットフォーム | |
| WO2017058866A1 (en) | Anti-trem2 antibodies and uses thereof | |
| CN114258400A (zh) | 用于改进的单链可变片段的材料和方法 | |
| JP2010536396A5 (enExample) | ||
| JP2019533466A (ja) | Ｃｄ４０およびｃｄ１３７に対する多重特異性抗体 | |
| CN113527501B (zh) | 抗cd73-抗pd-1双特异性抗体及其用途 | |
| EP3601368A1 (en) | Tumor antigen presentation inducer constructs and uses thereof | |
| WO2017166804A1 (zh) | 抗pd-1的单克隆抗体 | |
| JP2014111644A5 (enExample) | ||
| JP2024170410A (ja) | Ｔ細胞媒介性免疫を調節するための材料及び方法 | |
| CA3163304A1 (en) | Modified immune effector cell and preparation method therefor | |
| WO2022111576A1 (en) | Novel conjugate molecules targeting cd39 and tgfβeta | |
| CN112601761A (zh) | 结合ox40的多肽及其用途 | |
| Holgate et al. | Characterisation of a novel anti-CD52 antibody with improved efficacy and reduced immunogenicity | |
| CA3219606A1 (en) | Heterodimeric fc domain antibodies | |
| WO2015172341A1 (zh) | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 | |
| KR20240111798A (ko) | 항-trem2 항체를 사용한 섬유증 치료 | |
| Lao-Gonzalez et al. | Screening and selection strategy for the establishment of biosimilar to trastuzumab-expressing CHO-K1 cell lines | |
| CN116847863A (zh) | 抗人cd22的单克隆抗体及其用途 | |
| JP2025510719A (ja) | 選択マーカーとしての新規グルタミン合成酵素変異体 |